MOTS-c
A cutting-edge mitochondrial peptide being studied for energy metabolism and cellular health. Early research is promising but it is still very new — no FDA approval yet.
This peptide is not FDA-approved for any indication. Human use outside of clinical trials is not recommended.
The basics
- Generic Name
- MOTS-c (mitochondrial-derived peptide)
- Brand Names
- None (not an approved product)
- Regulatory Status
- Early Research
- Therapeutic Areas
- Metabolic & Weight Management, Endocrine
Wellness Goals
Important: This peptide is not yet FDA-approved
MOTS-c has not been approved by the FDA for any use in humans. That means it hasn't gone through the rigorous testing process that confirms a drug is safe and effective. Products sold online have not been evaluated by any regulatory body.
What it does
MOTS-c (MOTS-c (mitochondrial-derived peptide)) is a synthetic peptide that researchers are studying, but it's not yet FDA-approved for any human use. Mitochondrial-derived peptide that regulates metabolic homeostasis by targeting the AMPK pathway, improving glucose metabolism and cellular energy production.
The research is still early. Most studies so far are in animals or lab settings, so we don't know for sure how well this translates to real-world results in people.
How it's taken
Subcutaneous injection
How people access it
Currently only available through research peptide vendors labeled "for research use only." Not approved for human use and not available through pharmacies or compounding. No quality or purity guarantees exist for research-grade products.
Regulatory Status
Not FDA-approved. Emerging research peptide with growing interest in longevity and metabolic health.
Any use in humans outside of an FDA-authorized clinical trial would require an Investigational New Drug (IND) application. Products marketed as “for research use only” are not legally intended for human administration.
What the Evidence Shows
The evidence base for MOTS-c consists primarily of preclinical studies (animal models and in vitro experiments). There are no completed, large-scale, peer-reviewed clinical trials establishing safety or efficacy in humans. The gap between promising animal data and proven human benefit is substantial — many compounds that show effects in animal studies fail to demonstrate safety or efficacy in human trials.
Marketing claims made by online sellers and “peptide clinics” frequently overstate the evidence and omit critical information about risks and unknowns.
Other options to consider
Depending on what you're hoping to achieve, there may be FDA-approved treatments that have been rigorously tested and proven to work. Discuss evidence-based options with your own healthcare provider to find what fits your specific goals.
Browse our full peptide directory to see FDA-approved options that might work for you.
Common Questions
MOTS-c is unique because it's a mitochondrial-derived peptide — it's encoded in your mitochondrial DNA, not your nuclear DNA. This makes it part of a relatively new class of peptides that researchers are still learning about.
Human research on MOTS-c is very early stage. Most of what we know comes from animal studies and cell culture. While the results are intriguing, we're still a long way from understanding how it works in people.
Animal studies suggest MOTS-c may improve exercise capacity and metabolic function. But translating animal results to humans is always uncertain, and no clinical trials have confirmed these effects in people yet.
Curious about what IS approved?
Check out FDA-approved peptides that address similar goals — with established safety profiles and real clinical evidence.
See Approved Options